Clearpoint Neuro is trading at $12.42, up +5.53% during the September 30 session, with no specific catalyst identified. - No new Clearpoint Neuro announcement explaining the rebound surfaced in the search. - The September 29 selloff followed partner uniQure’s Huntington’s disease therapy data; coverage linked the setback to concern about future delivery-related revenue. - Broader U.S. indexes are higher and may support the bounce, but reporting does not establish a specific cause for today’s gain.